STAT3 and Miyoshi myopathy: The combination of CuB and Adriamycin exhibited a synergistic inhibitory effect on RPMI8226 cell growth (Figure 4D), further suggesting that activation of STAT3 plays an important role in MM, and providing a rationale for combination therapy using a STAT3 inhibitor and other chemotherapeutic drugs.